Arbutus Biopharma Reaches Analyst Target Price
July 03, 2018 at 07:46 AM EDT
In recent trading, shares of Arbutus Biopharma Corp (ABUS) have crossed above the average analyst 12-month target price of $7.75, changing hands for $7.85/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..